Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute... see more

Recent & Breaking News (NDAQ:ALNY)

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Business Wire March 30, 2026

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Business Wire March 24, 2026

Alnylam to Webcast TTR Investor Webinar

Business Wire March 10, 2026

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

GlobeNewswire March 5, 2026

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Business Wire February 23, 2026

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

Business Wire February 12, 2026

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Business Wire January 29, 2026

Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact

Business Wire January 11, 2026

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2026

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Business Wire December 17, 2025

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Business Wire December 11, 2025

Alnylam Pharmaceuticals Announces Changes to Board of Directors

Business Wire December 3, 2025

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Business Wire November 8, 2025

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Business Wire November 4, 2025

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Business Wire October 30, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Business Wire October 16, 2025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Business Wire October 1, 2025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Business Wire September 28, 2025

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

PR Newswire September 18, 2025

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Business Wire September 9, 2025

Podcasts